SFARI

Tammi Fumberi joined the Simons Foundation in 2015, bringing with her extensive experience in healthcare administration and event management. Previously, Fumberi worked as an administrative assistant at MedStar Georgetown University Hospital, coordinating the operations and personnel for the hospital’s Language and International Services program. Prior to that, she served for seven years as an operations associate in the Medical Intensive Care Unit at Massachusetts General Hospital.

Karen Walton-Bowen joined Clinical Research Associates in 2014 to oversee clinical operations, biostatistical analysis and reporting, and the arbaclofen program. Walton-Bowen is an expert in clinical development across multiple therapeutic areas within the pharmaceutical and biotechnology industry, including gastrointestinal, neuroscience, respiratory, cardiovascular, lysosomal storage disorders, inflammation and pain control.

Ann Marie Craig is professor of psychiatry and Canada Research Chair in Neurobiology at the University of British Columbia and is a member of the Royal Society of Canada. She began her studies on synapses as a postdoctoral fellow with Gary Banker and held previous faculty positions at the University of Illinois and at Washington University in St. Louis.

Heather C. Mefford, is a Member, Faculty at St. Jude's Hospital in Memphis, Tennessee. Mefford has a research laboratory devoted to the discovery of novel genetic and genomic causes of pediatric disease. 

Charles Craik is a professor in the Department of Pharmaceutical Chemistry at the University of California, San Francisco (UCSF). He is also the founder and director of the Chemistry and Chemical Biology Graduate Program.

John Rubenstein is a professor at the University of California, San Francisco. The goal of his laboratory’s research is to elucidate fundamental mechanisms that regulate development of the forebrain, with a focus on the cerebral cortex and basal ganglia. The studies in his laboratory also extend into other regions of the embryo, including the developing face. Whenever possible, Rubenstein attempts to investigate whether disruption of these mechanisms underlie human disorders, such as autism, schizophrenia, intellectual disability, epilepsy and craniofacial disorders. The overarching hope is that these studies provide insights and new inroads into diagnosis, prevention and treatment of these disorders.

Craig Erickson specializes in research and clinical treatment involving persons with developmental disorders. His primary research focus is on new treatment development for fragile X syndrome, autism spectrum disorders and other related disorders.

He is the director of the Fragile X Research and Treatment Center and also serves as the director of research at the Kelly O'Leary Center for Autism Spectrum Disorders.

Gerald Crabtree is the David Korn Professor at Stanford University School of Medicine. He has been a Simons Foundation Autism Research Initiative Investigator since 2014 and a Howard Hughes Medical Institute investigator since 1988.